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 Introduction 
 Ventricular septal defects (VSDs) are the most com-
mon congenital cardiac defects, and account for approx-
imately 20% of all congenital heart diseases  [1] . They are 
classified according to their location in the septum  [2] . 
Muscular VSDs (mVSDs) account for approximately 10–
15% of all VSDs  [3] .
 Hemodynamic significance depends on the size of the 
VSDs, the pressure in the right and left ventricle, and the 
pulmonary vascular resistance. The shunt volume is 
largely determined by the size of the defect and the pul-
monary resistance. Symptoms depend on the relevance of 
the VSD and range from congestive heart failure to de-
layed growth and development, paleness, shortness of 
breath or arrhythmias  [4] . The final stage of untreated 
VSDs is Eisenmenger’s syndrome with irreversibly ele-
vated pulmonary arterial pressure (PAP). Thus, therapy 
must be accurately timed. While most defects above the 
moderator band can be surgically closed by a transatrial 
approach from the right side, definitive treatment for 
complex mVSDs beyond the moderator band is still chal-
lenging,      particularly     in     small     infants.     Both     approach-
es – surgical and interventional – have their limitations. 
Especially, mVSDs beyond the moderator band may re-
quire left ventriculotomy, or the division of multiple im-
portant right-sided muscle bands when using a right atri-
al approach. This course of action is associated with long-
term morbidity  [5, 6] , prolonged admission and scar 
formation  [4] . The rate of reoperation due to residual 
 Key Words 
 Animal models   Muscular ventricular septal defects   
Muscular ventricular septal defect closure, therapeutic 
strategies  
 Abstract 
 Background/Aims: So far, surgical and interventional thera-
pies for muscular ventricular septal defects (mVSDs) beyond 
the moderator band have had their limitations. Thus, alter-
native therapeutic strategies should be developed. We pres-
ent a new animal model for the evaluation of such strategies. 
 Methods: In a pig model (n = 9), anterolateral thoracotomy 
was performed for exposure of the left ventricle. mVSDs 
were created under two- and three-dimensional echocar-
diography with a 7.5-mm sharp punch instrument, which 
was forwarded via a left ventricular puncture without extra-
corporeal circulation.  Results: Creation of mVSDs was suc-
cessful in all animals (n = 9) confirmed by echocardiography, 
hemodynamic measurements and autopsy. The defects 
were located in the midmuscular (n = 4), apical (n = 1), inlet 
(n = 2) and anterior part (n = 2) of the muscular septum. All 
animals were hemodynamically stable for further proce-
dures. The diameter and shunt volume of the mVSDs were 
4.8–7.3 mm (mean: 5.9 mm) and 12.9–41.3% (mean: 22.1%), 
respectively. Autopsy confirmed in all animals the creation 
of a substantial defect.  Conclusion: The described new tech-
nique for creation of an mVSD on the beating heart in a pig 
model is suitable for the evaluation of new therapeutic strat-
egies for mVSD closure.  Copyright © 2008 S. Karger AG, Basel 
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shunts after mVSD closure using right atriotomy is re-
ported to be up to 10%  [7] . Furthermore, surgery requires 
extracorporeal circulation (ECC), which may be associ-
ated with different adverse effects  [8–10] .
 The alternative of interventional strategies are limited 
by poor vascular access, especially in small infants  [11] . 
The use of big sheaths can cause severe rhythm distur-
bances and hemodynamic deterioration during the pro-
cedure. The most commonly used Amplatzer devices are 
working with a stenting mechanism and are associated 
with significant arrhythmias, hemodynamic impair-
ment, valve injury or incomplete closure  [12, 13] .
 Thus, exploration of novel therapeutic strategies is 
reasonable. For assessment, a valid animal model for 
evaluation and establishment of new approaches has not 
yet been published. Here we report about a new technique 
to create mVSDs on the beating heart in pigs.
 Materials and Methods 
 Animals 
 We used German Landrace piglets of either sex (n = 9, weight 
20–30 kg), which were purchased from the local farm of the Uni-
versity of Munich (Oberschleissheim, Germany). The experimen-
tal protocol was approved by the local Governmental Commis-
sion on the Care and Use of Animals. The animals received care 
in  compliance  with  the  Guide  for  the  Care and Use of Laborato-
ry  Animals. All experiments were performed in the Laboratory 
of Surgical Research, Walter Brendel Center for Experimental 
Medicine, at the Ludwig Maximilian University of Munich, Ger-
many.
 Anesthesia 
 The piglets were fasted overnight and premedicated intramus-
cularly with 500 mg ketamine, 10 mg/kg body weight azaperone 
and 0.5 mg atropine. Midazolam (0.1 mg/kg body weight) was 
administered intravenously via an ear vein. The animals were in-
tubated with a 6.5-mm tube and ventilated with an FiO 2 of 50%. 
General anesthesia was induced and maintained with propofol 
(1.5–2 mg/kg body weight/h, maintenance 10 mg/kg body weight/
h) and fentanyl (0.02 mg/kg body weight/h, maintenance 0.045 
mg/kg body weight/h). Ventilation was adjusted to keep arterial 
pCO 2 between 35 and 45 mm Hg. Arterial blood samples were 
obtained for analyses of pO 2 , pCO 2 and pH. Prior to thoracotomy, 
muscle paralysis was induced with pancuronium bromide, 0.1 
mg/kg body weight intravenously, with single additional  doses if 
necessary.
 Ringer solution was given at a base rate of 10 ml/kg body 
weight/h. Hydroxyethyl starch 6% was administered in case of 
relevant blood loss. Oxygenation, ECG and temperature were 
monitored continuously throughout the study. 
 Amiodarone (20 mg/kg body weight/day) and magnesium 
(3 mmol) were given intravenously throughout the whole study to 
prevent ventricular arrhythmias . 
 Surgical Preparation 
 First all animals were shaved for thoracotomy and neck dis-
section on the right side. The external carotid artery and the jug-
ular vein were dissected, and cannulated with a 9-french and an 
11-french introducer sheath, respectively, for continuous arterial 
(AP) and central venous pressure (CVP) monitoring. 
 Animals were placed in dorsolateral recumbency with the left 
side upward. Left 4th intercostal thoracotomy was performed and 
the heart was exposed by opening the pericardium.
 Imaging 
 For imaging, two- and three-dimensional echocardiography 
was used. For two-dimensional echocardiography (Sonos 5500, 
Philips Medical Systems, The Netherlands), a 5-MHz transesoph-
ageal echocardiographic probe was put behind the beating heart 
via an incision in the 6th intercostal space. Three-dimensional 
echocardiography was performed epicardially by using the X7-2 
matrix transducer of the IE33 Ultrasound System (Philips Medi-
cal Systems, The Netherlands).
 Creation of mVSDs 
 The entire procedure was performed without the use of ECC. 
Creation of mVSDs was achieved using a specially designed punch 
instrument. It contained a trocar and a superimposed sharp hol-
low needle ( fig. 1 ; Müller Instrumente GmbH, Tuttlingen, Ger-
many). Purse-string sutures were applied on the apical left ven-
tricular wall to minimize blood loss during the creation proce-
dure. The instrument was inserted into the left ventricle via a left 
ventricular puncture ( fig. 2 a). Subsequently, the trocar was re-
trieved, and the open end of the hollow needle was closed with an 
appropriate plug ( fig. 1 ,  2 b).
 The following procedure was done under continuous two-di-
mensional and three-dimensional echocardiographic control. 
The hollow needle was forwarded towards the muscular septum. 
After positioning the hollow needle at the desired portion of the 
septum, an mVSD was created by rotating the hollow needle con-
tinuously towards the septum.  Figure 2 demonstrates the prin-
 Fig. 1. The punch instrument for creation of mVSDs. It consists of 
three pieces: a trocar, a sharp hollow needle and a plug. 
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ciple of our technique ex vivo. By adjusting the position of the 
hollow needle the defects could be varied regarding their orienta-
tion to the inlet, anterior, middle or apical portion of the sep-
tum.
 Successful creation of an mVSD was confirmed by echocar-
diographic visualization with sizing of the VSD and measure-
ments of the shunt volume by the Fick method as well as explanta-
tion of the heart. Finally, animals were euthanized by an intracar-
dial injection of 40 mval KCl. Autopsy of the hearts was performed 
for exact location of the defects.
 Measurements 
 Arterial blood samples were obtained every 60 min to control 
appropriate ventilation. Heart rate, AP and CVP were monitored 
continuously. Mean AP (MAP), CVP, PAP and pulmonary capil-
lary wedge pressure (PCWP) were obtained at baseline, before 
thoracotomy and after creation of the shunt.
 Statistical Analysis 
 Values are presented as means  8 standard deviation. For 
comparison of different groups, the paired t test was used. A p 
value  ! 0.05 was considered as statistically significant.
 Results 
 Basal echocardiography excluded cardiac defects and 
valve insufficiencies in the animals. The surgical proce-
dure was well tolerated by all animals (n = 9). Hemody-
namic parameters were stable during the surgical proce-
dure in all animals without administration of catechol-
amines. There was a slight decrease in MAP and CVP 
values without statistical significance ( fig. 3 a). 
a b
c d
 Fig. 2. Demonstration of the creation of mVSDs ex vivo.  a The first step of creation of VSDs is to forward the 
punch instrument via a left ventricular incision into the left ventricle.  b Afterwards the trocar is retrieved and 
the remaining hollow needle is closed with a plug.  c The hollow needle penetrating the muscular septum is 
demonstrated.  d Our method creates a substantial defect into the muscular septum. 
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 PAP and PCWP values showed a trend towards an in-
crease although not statistically significant. Accordingly, 
there was a development of mild pulmonary hyperten-
sion and left ventricular dysfunction ( fig. 3 b).
 Creation of an mVSD was successful in all animals 
confirmed by echocardiography and measurement of the 
shunt volume ( fig. 4 ,  5 ). The echocardiographic diameter 
of the mVSDs ranged from 4.8 to 7.3 mm (5.9  8 0.9 mm); 
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 Fig. 3. Hemodynamics throughout the experiment. MAP (A, B) 
and CVP (C, D) ( a ), and PAP (A, B) and PCWP (C, D) ( b ) mea-
surements before (A, C) and after creation (B, D) of the defect. It 
is obvious that there is only a slight decrease in MAP and CVP.
 b Development of a mild pulmonary hypertension and left ven-
tricular dysfunction. 
 Fig. 4. A representative midmuscular VSD without ( a ) and with 
( b ) residual tissue in two-dimensional echocardiography (LV = 
left ventricle; RV = right ventricle). Strong left-to-right shunts are 
seen in both panels. Flow away from the transducer is coded blue, 
flow towards the transducer is coded red.  b There is no obstruc-
tion of the mVSD by the residual tissue at its edge. 
 Fig. 5. A representative midmuscular VSD in three-dimensional 
echocardiography. A piece of muscular septum is shown with ev-
ident left-to-right shunt. 
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shunt volumes were calculated between 12.9 and 41.3% 
(mean  22.1   8   16.0%).   The   Qp:Qs   ratios   varied   from  
1.2: 1 to 1.7: 1. Explantation of the heart revealed the exact 
location of the VSDs ( fig. 6 ). The defects were located in 
the distal apical muscular (n = 1), anterior muscular (n = 
2), midmuscular (n = 4), and inlet muscular (n = 2) region 
of the muscular septum ( table 1 ). Furthermore, it was ob-
vious that substantial defects were created. A correlation 
of diameter and shunt volumes was not found. 
 There was a small muscle bridge left at one edge of the 
defect on the right side of the septum after the procedure 
in 8 out of 9 animals ( fig. 4 b). Substantial swelling of the 
surrounding area was noted in all animals. 
 Discussion 
 The present study describes a new technique to create 
mVSDs without using ECC in pigs. This animal model 
serves to evaluate and establish new interventional and 
hybrid therapies for closure of mVSDs. 
 The conventional therapy of mVSDs is surgery. Mus-
cular defects above the moderator band can be treated by 
a transatrial approach. However, mVSDs localized be-
yond the moderator band still remain a technical chal-
lenge. If a primary repair is not possible, a pulmonary 
banding can be done in order to delay definitive surgery. 
In these cases, left ventriculotomy is often performed and 
can result in long-term complications  [5, 6] . Surgery is 
generally associated with side effects such as prolonged 
admission, scar formation, and discomfort  [4] . Further-
more, surgery requires ECC which may be associated 
with various adverse effects such as impaired neurologi-
cal development  [9, 10] or systemic inflammatory re-
sponse syndrome  [8] . Recently, interventional therapy for 
closure of mVSDs has shown promising results  [12, 14, 
15] . However, major limitations are the challenging pro-
cedures, low patient weight or poor vascular access  [11] . 
Additionally, rhythm disturbances and hemodynamic 
instability especially in small infants have been reported 
 [14] .
 Hybrid therapy, combining the advantages of surgical 
and interventional techniques, is a promising approach 
for closure of mVSDs  [16–19] . Besides advantages, there 
are still complications such as device embolization into 
the aorta or valve injuries.
 Thus, new therapeutic strategies for mVSD closure 
have to be developed. These new approaches have to be 
tested in an animal model prior to human application. 
Amin et al. [20] reported of the creation of mVSDs in dogs 
Table 1. Size of the mVSDs and the location in the septum
Pig No. Diameter, mm Location 
1 5.0 midmuscular
2 6.3 inlet muscular
3 4.8 anterior muscular
4 4.8 apical
5 6.7 midmuscular
6 6.3 midmuscular
7 5.1 anterior muscular
8 6.0 midmuscular
9 7.3 inlet muscular
a
b
 Fig. 6. Demonstration of a representative mVSD in an explanted 
heart.  a mVSD from the right ventricular side.  b mVSD from the 
left ventricular side. It is obvious that a substantial mVSD was cre-
ated. 
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with an intraoperative success rate of 85%. There are rel-
evant differences between the animal model described by 
Amin et al. and ours. They used median sternotomy. Fur-
thermore, they created the mVSD from the right ventric-
ular side. 
 We believe that pigs can hardly survive after median 
sternotomy, as fixation of the sternum is nearly impos-
sible. Thus, we established an animal model with left an-
terolateral thoracotomy as an approach. Consequently, 
the mVSDs were created from the left ventricular side.
 We demonstrate the feasibility of a novel technique for 
creation of mVSDs in a pig model. Echocardiographic vi-
sualization of the procedure with a transesophageal echo-
cardiography probe put behind the beating heart was ex-
cellent and comparable to conventional transesophageal 
echocardiography. The incision for the probe can be used 
for insertion of a chest drain in a chronic animal study. 
Echocardiography and measurements of shunt volumes 
after the procedure confirmed successful and reproduc-
ible creation in 100% in contrast to 85% in the dog animal 
model  [13] . 
 We used piglets weighing up to 20–30 kg to evaluate a 
general feasibility of our technique. The punch instru-
ment may easily be modified from standard instruments. 
The diameter can be changed as needed. We believe that 
the same technique may also be used for creation of
mVSDs in piglets weighing below 10 kg with smaller 
punch instruments. However, very young piglets may be-
come more hemodynamically instable than older ones. 
Thus, the mVSDs should be induced by an experienced 
person. We are aware that therapeutic strategies should 
also be evaluated in piglets weighing below 10 kg.
 We decided to use a 7.5-mm punch to avoid acute pul-
monary hypertension and left ventricular dysfunction 
with acute deterioration of the circulation. We observed 
a discrepancy between unexpectedly small Qp:Qs ratios 
and substantial defects in autopsy. This may be due to 
myocardial swelling which could be observed after the 
procedure in echocardiography. Development of pulmo-
nary hypertension was only mild. After vanishing of the 
edema the shunts might increase. Consequently, devel-
opment of relevant pulmonary hypertension seems like-
ly. If in acute experimental designs bigger shunts are rec-
ommended, the punch instrument should have an in-
creased diameter of up to 10 mm. In our general 
feasibility studies the animals with a 7.5-mm punch 
showed excellent hemodynamic stability without rele-
vant pulmonary hypertension or left ventricular dys-
function. Thus, evaluating new techniques in the same 
session seems possible.
 Our model can be used for evaluating new therapeutic 
strategies for mVSD closure prior to human application. 
An acute and chronic design of these experiments seems 
to be possible. 
 In an acute design, the mVSDs can be closed during 
the same session. Because of the excellent hemodynamic 
stability of the pigs, therapeutic strategies can extensive-
ly be tested.
 Furthermore, it might also be possible to end the op-
eration after creation of the defect, and extubate the ani-
mals. After animals recovered from surgery, maybe after 
3–6 weeks, evaluation of therapeutic strategies could be 
done in a second session.
 Furthermore, a chronic design of the experiments also 
seems to be feasible. This was one reason why we used 
anterolateral thoracotomy instead of median sternotomy. 
Thus, animals can survive after closing the mVSD with a 
new technique. Long-term consequences of new tech-
niques such as efficacy of the technique or left ventricular 
dysfunction can be evaluated. Recently, improvements in 
myocardial tissue engineering, e.g. construction of con-
tractile patches, have been made. Until now, primarily 
large animal models are needed for evaluation of these 
patches. Our animal model can also serve this purpose. 
Thus, this pig model can be used to evaluate and establish 
novel therapeutic strategies either during the same op-
eration or in a second session. 
 Another application area could be the investigation of 
pulmonary hypertension. We believe that it might be 
possible to wake up the animals after creation of the VSD. 
This would allow to reinvestigate them after 4–6 weeks. 
Then, development of pulmonary hypertension seems 
likely as the edema may vanish after 2 weeks and the 
shunt volume increases.
 In addition, we saw a small tissue bridge at one edge of 
the mVSD at the right side of the septum after creation of 
the defect. The reason for this finding is the angle be-
tween the punch instrument and the muscular septum. 
Usually, it will not be 90° and a small tissue bridge will 
remain between the muscular material punched out and 
the septum on the right ventricular side. Because of the 
left-to-right shunt it is unlikely that this tissue will ob-
struct the VSD. In a chronic setting, this might cause pul-
monary embolism at the segment artery level.
 Autopsy of the heart revealed four different locations 
of  the  created mVSDs, so that different subtypes of 
 mVSDs can be tested for closure. The location of the de-
fects can be controlled by echocardiography. Apical de-
fects are most difficult to create as the right ventricular 
wall can be punctured. 
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 In summary, we established a new technique to create 
mVSDs without ECC under echocardiographic guidance 
in a pig model. We plan to use this model to test new hy-
brid devices for VSD closure. We hope this information 
may be helpful for other authors dealing with the creation 
and treatment of mVSDs.
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